---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035377"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T04:41:35.308750+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Bioxytran registers Indian subsidiary, Pharmalectin India, to commercialize ProLectin-M pending CDSCO approval

## Summary
- Wholly owned subsidiary Pharmalectin India Private Limited registered on Sept 7, 2022 in India.
- Subsidiary to sponsor clinical trials and commercialize Bioxytran's products if CDSCO approval is obtained.
- Indian manufacturing plant is FDA-approved; no distributor identified yet.
- Press release and updated corporate presentation issued Dec 14, 2022.

## SEC filing metadata
- accession: 0001493152-22-035377
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315222035377/0001493152-22-035377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315222035377/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035377
- JSON: https://secwatch.observer/filing/0001493152-22-035377.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.